Departed
Jake Singleton
Chief Financial Officer
JYNT ·
JOINT Corp
Effective June 9, 2025, Jake Singleton separated from our company as our Chief Financial Officer.
Ready 8-Ks
50
Latest filing
May 21, 2026, 4:32 PM ET
Top materiality
0.85
Event mix
earnings ×22 · other_material ×9 · leadership ×6
Sentiment
9 pos · 15 neg · 26 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for JYNT
Highest-materiality recent filing
The Joint Corp. sells 45 Southern California clinics for $2.3M, moves to pure franchisor model
- 45 clinics sold to Elite Chiro Group for $2.3M; 13 closed on April 27, 2026.
- 32 clinics under management service agreement until lease assignments are completed.
-
JYNT Q1 revenue up 13%, net income up 34%; credit covenant default waived
Revenue $14.8M (+13% YoY); net income from continuing ops $1.1M vs loss $506K prior year.
-
The Joint Corp. sells 45 Southern California clinics for $2.3M, moves to pure franchisor model
45 clinics sold to Elite Chiro Group for $2.3M; 13 closed on April 27, 2026.
-
Joint Corp. agrees to sell 45 Southern California clinics to Elite Chiro Group for $2.3M
Total purchase price $2.3M, includes $150k non-refundable down payment; remainder paid into escrow.
-
Q4 revenue $15.2M (+3.1% YoY); net income from continuing ops $937K vs $909K.
-
Joint Corp. agrees to nominate activist investor Jefferson Gramm to board
Letter agreement with Bandera Partners LLC requires company to include Jefferson Gramm in director slate for 2026 annual meeting.
-
Joint Corp. agrees to nominate activist investor Jefferson Gramm to board at 2026 annual meeting
Company will nominate Jefferson Gramm (Bandera Partners) and recommend his election at 2026 annual meeting.
-
Joint Corp signs $1.5M APA for 22 SE clinics, terminates $4.5M APA for 45 CA clinics
Sold 22 clinics in VA, NC, SC for aggregate purchase price of $1,482,800; buyers are existing franchisees/operators.
-
Joint Corp Q3 net income turns positive to $855K; sells 45 clinics for $4.5M; adds $12M buyback
Q3 revenue $13.4M (+6% YoY); consolidated net income $855K vs loss of $3.2M in Q3 2024.
-
The Joint Corp. to refranchise all company clinics; credit maturity extended to Aug 2027
Consent to refranchise 100% of company-owned/managed clinics to franchisees by Dec 31, 2025.
-
Joint Corp Q2 rev $13.3M +5%, narrows loss; cuts FY system-wide sales guidance to $530-550M
Q2 revenue $13.3M (+5% YoY); consolidated net income $93K vs loss $3.6M; net loss from continuing ops $990K vs loss $1.7M.
-
Expects to reduce 2024 net loss by ~$2.2M and increase carrying value of assets held for sale by ~$2.2M.
-
The Joint Corp. closes sale of 31 clinics for $11.13M, acquires NW region RD rights
Sold 31 company-owned clinics in AZ/NM to Joint Ventures, LLC for $11.13M (includes $8.3M cash).
-
The Joint sells 31 clinics for $11.07M, acquires NW region rights, refranchises 5 clinics
Sale of 31 corporate clinics to Joint Ventures, LLC for $11.07M; buyer to own 96 clinics total.
-
The Joint Corp. Q1 revenue up 7% to $13.1M; net loss widens to $506k; reiterates 2025 guidance
Q1 revenue $13.1M (+7% YoY); system-wide sales $132.6M (+5%); comp sales 3%.
-
The Joint Corp reports Q4 revenue up 14%, 2025 guidance for lower EBITDA
Q4 revenue from continuing operations $14.4M (+14% YoY); net income $986k vs loss $10.2M.
-
Performed 14.7 million patient visits in 2024, up from 13.6 million in 2023.
-
The Joint Corp. enters into Amended Nomination and Standstill Agreement with Bandera Partners
Agreement dated Dec 19, 2024 amends prior standstill agreement between The Joint Corp. and Bandera Partners LLC.
-
Joint Corp Q3 net loss $3.2M; guides down system-wide sales and new openings
Revenue $30.2M (+2% YoY); net loss $3.2M vs $716K loss in Q3 2023, including $3.8M impairment.
-
Joint Corp appoints Sanjiv Razdan as CEO; Peter Holt resigns
Peter D. Holt resigned as President/CEO and board member effective Oct 10, 2024.
-
Joint Corp Q2 net loss $3.6M ($0.24/sh); revenue $30.3M up 3% YoY; guidance reaffirmed
Net loss $3.6M ($0.24 loss per share) vs net loss $320K ($0.02 loss) in Q2 2023.
-
Joint Corp. stockholders approve 2024 Incentive Stock Plan with 2M shares authorized
Plan authorizes up to 2,000,000 shares for stock options, SARs, restricted stock, and RSUs.
-
Joint Corp Q1 rev $29.7M (+5% YoY), operating income $1.1M, reiterates guidance
Revenue $29.7M (+5% YoY); operating income $1.1M vs loss $653k; net income $0.06/diluted share.
-
Q4 2023 revenue grew 11% to $30.6M; system-wide sales up 11% to $133.1M
-
Joint Corp Q3 net loss $716K; plans to refranchise majority of corporate clinics
Revenue $29.5M (+11% YoY); net loss $0.05/sh vs income $0.05/sh in Q3 2022.
-
Restatement covers audited FY2021, FY2022, and interim 2021/2022 quarters; all prior financial statements no longer reliable.
-
Joint Corp. Q2 prelim: rev $29.3M (+18%), Adj EBITDA $3.2M (+23%), cuts FY guidance
Revenue $29.3M (+18% YoY); operating loss improved to $0.375M from $1.3M loss in Q2 2022.
-
Default triggered by failure to timely file Q2 2023 10-Q; JPMorgan waived until Sept 30, 2023.
-
The Joint Corp. to restate 2022 results; net income to drop $0.6M due to accounting errors
Restating 2022 annual and interim financials for re-acquired regional developer rights and VIE transfer pricing errors.
-
Joint Corp. gets Nasdaq delinquency notice for late Q2 2023 10-Q filing
Nasdaq notice received Aug 22, 2023 due to failure to file Q2 2023 Form 10-Q by Aug 21 deadline.
-
The Joint Corp. Q2 system-wide sales +13% to $120.1M; financial results postponed due to review
System-wide sales $120.1M (+13% YoY); system-wide comp sales +5%.
-
Joint Corp Q1 revenue up 27% to $28.5M; net income $2.3M includes $3.9M ERC credits
Revenue $28.5M (+27% YoY); system-wide sales $115.4M (+17%); system-wide comp sales +8%.
-
Q4 revenue $27.8M (+26% YoY); system-wide comp sales +8%; total clinics 838 at year-end.
-
The Joint Corp Q3 revenue +27% to $26.6M; net income drops to $491k; lowers EBITDA guidance
Revenue $26.6M (+27% YoY); net income $491k ($0.03 EPS) vs $1.9M ($0.13) in Q3 2021.
-
The Joint Corp Q2 revenue rises 24% to $25.1M, net income plunges to $345k from $2.7M
Revenue $25.1M (+24% YoY); net income $345k ($0.02 EPS) vs $2.7M ($0.18) prior year.
-
The Joint Corp. acquires four franchised clinics for $5.8M; expects immediate accretion
Total consideration $5.8M: $5.6M cash at close, $200K within 90 days.
-
The Joint Corp. Q1 revenue $22.4M (+28% YoY); net loss $206K; adj. EBITDA $1.8M; updates guidance
Revenue $22.4M, up 28% YoY; system-wide sales $98.8M (+27%); comp sales +15%.
-
Joint Corp. expands senior secured revolver to $20M; uncommitted line to $30M
Revolver increased from $2M to $20M; letter of credit subfacility from $1M to $5M.
-
Joint Corp. reports 38% revenue growth in FY2021; corrects 2022 clinic opening guidance to 110-130
Q4 revenue $22.4M (+32% YoY); net income $224K vs $10.6M (prior year benefitted from $8.9M tax valuation allowance reversal).
-
Joint Corp. Q4 revenue $22.4M (+32% YoY); net income $224K; guides FY22 rev $102-106M
Full-year 2021 revenue $81.2M (+38% YoY); system-wide sales $361.1M (+39%).
-
Joint Corp Q3 revenue $21.0M (+36% YoY), net income $1.9M; raises FY guidance
Revenue $21.0M (+36% YoY), system-wide sales $93.4M (+37%), system-wide comp sales +27%.
Executive changes
Appointed
Scott J. Bowman
Chief Financial Officer
JYNT ·
JOINT Corp
Effective June 10, 2025, our Board of Directors (the “Board”) appointed Scott J. Bowman as our Chief Financial Officer.
Appointed
Sandra R.A. Karrmann
Director
JYNT ·
JOINT Corp
On June 3, 2025, our Board of Directors (the “Board”) increased the size of the Board by one director and appointed Sandra R.A. Karrmann to fill the vacancy created by the increase in size of the Board.
Appointed
Sanjiv Razdan
President and Chief Executive Officer
JYNT ·
JOINT Corp
Effective October 14, 2024, the Board of Directors of the Company appointed Sanjiv Razdan as President and Chief Executive Officer of the Company and as a member of the Company’s Board of Directors.
Departed
Peter D. Holt
President and Chief Executive Officer
JYNT ·
JOINT Corp
Effective October 10, 2024, Peter D. Holt resigned as President and Chief Executive Officer of The Joint Corp. (the “Company”) and as a member of the Company’s Board of Directors.
Appointed
Jeff Gramm
Director
JYNT ·
JOINT Corp
the Board agreed to appoint Mr. Gramm to the Board effective as of January 2, 2024
Departed
James H. Amos, Jr.
Director
JYNT ·
JOINT Corp
On March 7, 2023, Mr. James H. Amos, Jr., a director of The Joint Corp. (the “Company”) notified the Company that he will not stand for reelection at the Company’s 2023 Annual Meeting of Stockholders.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.70 · Most common event earnings